Current status of BCG and OPV vaccination in children with primary immunodeficiency in Chongqing, China

中国重庆市原发性免疫缺陷儿童卡介苗和口服脊髓灰质炎疫苗接种现状

阅读:1

Abstract

This study actively monitors patients with primary immunodeficiency under the age of 18 to understand the risk of adverse reactions after vaccination and provide references for developing vaccination evaluation measures for children with special health conditions. A questionnaire survey was conducted on patients diagnosed with primary immunodeficiency, collecting diagnosis and treatment information as well as the vaccination records of live vaccines. Two stool samples were collected for virus detection and the vaccine-derived poliovirus was analyzed. A total of 26 primary immunodeficiency patients were enrolled among 3312 monitored cases, including 5 cases of severe combined immunodeficiency, 7 cases of primary antibody deficiency, and 14 cases of other types of immunodeficiency. Among the 21 cases with clear vaccination records, the vaccination rate of BCG and oral poliovirus vaccine were 95.24% and 71.43%, respectively. Among them, the vaccination rates of both vaccines for patients with severe combined immunodeficiency were 100% and 60.00%, respectively; and for patients with primary antibody deficiency were 100%. It was found that 1 patient with severe combined immunodeficiency had disseminated BCG infection after vaccination, and type Ⅲ immunodeficiency-associated vaccine-derived poliovirus was detected in his stool samples. The proportion of primary immunodeficiency patients receiving live vaccines is high, and there is a risk of adverse reactions after vaccination. It is recommended to improve the awareness and ability of recognizing vaccination for children with immunodeficiency, promote the active monitoring of children with immunodeficiency in hospitals, and adjust the immunization strategy for polio vaccine in a timely manner.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。